Lonza receives Swissmedic approval for Biologics drug product filling line in Stein
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Subscribe To Our Newsletter & Stay Updated